TA
PACB icon

Tiedemann Advisors’s Pacific Biosciences PACB Stock Holding History

Tiedemann Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,700
Closed -$63K – 438
2018
Q3 		$63K Hold
11,700
– – ﹤0.01% 307
2018
Q2 		$42K Hold
11,700
– – ﹤0.01% 293
2018
Q1 		$24K Hold
11,700
– – ﹤0.01% 263
2017
Q4 		$31K Buy
+11,700
New +$41K ﹤0.01% 221
2017
Q2 		– Sell
-11,700
Closed -$60K – 449
2017
Q1 		$60K Hold
11,700
– – 0.01% 389
2016
Q4 		$45K Buy
+11,700
New +$85K ﹤0.01% 322

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tiedemann Advisors's PACB Position: Q4 2018 in Review

Tiedemann Advisors sold out of Pacific Biosciences (PACB) in Q4 2018, closing a stake of 11,700 shares — an estimated $63K sold.

Tiedemann Advisors first reported a position in PACB in Q4 2016 and held it in 6 quarters. The position peaked at $63K in Q3 2018. 155 funds tracked by Wall St. Rank hold PACB as of Q4 2018.

  • Tiedemann Advisors reported no remaining Pacific Biosciences position as of Q4 2018 after selling out during the quarter.
  • Tiedemann Advisors sold 11,700 Pacific Biosciences shares in Q4 2018, an estimated $63K.
  • Tiedemann Advisors first reported a position in Pacific Biosciences in Q4 2016 and held it in 6 quarters.
  • Tiedemann Advisors's Pacific Biosciences position peaked at $63K in Q3 2018.
  • 155 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2018.

Based on Tiedemann Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.